Loading...
Market
How many at-home FluMist nasal spray units will be sold in the first month of availability?
2
Resolution / Starting Odds
Less than 100,000 units • 25%
100,000 to 500,000 units • 25%
500,000 to 1 million units • 25%
More than 1 million units • 25%
Sales data from the third-party pharmacy platform.
Story
FDA Approves First At-Home FluMist Nasal Spray for Self-Administration
Sep 20, 2024, 08:36 PM
The U.S. Food and Drug Administration (FDA) has approved AstraZeneca's FluMist nasal spray influenza vaccine for self- or caregiver-administration. This marks the first time a flu vaccine can be administered at home without the need for a healthcare provider. The vaccine, which is licensed for individuals aged 2 to 49, will be available for order online through a third-party pharmacy platform starting next flu season. The approval is part of the FDA's broader effort to expand consumer access to medicines, reduce healthcare costs, and barriers to care. FluMist contains a weakened live virus and aims to prevent influenza caused by virus subtypes A and B. This self-administered alternative to flu shots is expected to increase accessibility and uptake of influenza immunization.
View original story
Similar markets
Yes • 50%
No • 50%
Less than 500,000 • 25%
500,000 to 1 million • 25%
1 million to 2 million • 25%
More than 2 million • 25%
Yes • 50%
No • 50%
1 to 2 million • 25%
Less than 1 million • 25%
2 to 3 million • 25%
More than 3 million • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Less than 1 million units • 25%
1 to 2 million units • 25%
2 to 3 million units • 25%
More than 3 million units • 25%
Less than 5% • 25%
5% to 10% • 25%
10% to 20% • 25%
More than 20% • 25%